SJ has received honoraria for educational talks given for Sunovian, and his employer, King's College London, has received honoraria for educational talks he has given for Lundbeck. AHY reports paid lectures and advisory boards for the following companies with drugs used in affective and related disorders: AstraZeneca, Eli Lilly, Lundbeck, Sunovion, Servier, Livanova, Janssen, Allegan, Bionomics, Sumitomo Dainippon Pharma, and COMPASS; is a consultant to Johnson & Johnson and Livanova; received honoraria for attending advisory boards and presenting talks at meetings organised by LivaNova; and was principal investigator in the Restore-Life VNS registry study funded by LivaNova, principal investigator on ESKETINTRD3004: “An open-label, long-term, safety and efficacy study of intranasal esketamine in treatment-resistant depression”, principal investigator on “The effects of psilocybin on cognitive function in healthy participants”, and principal investigator on “The safety and efficacy of psilocybin in participants with treatment-resistant depression (P-TRD)”. This work presents independent research part-funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London.